Generex Biotechnology Corporation (NASDAQ: GNBT), a biopharmaceutical company, has a diversified product portfolio designed to deliver innovative products to treat patients with cancer. DNA/RNA-based Medicines and Small Molecules are the two major programs that anchor the Company’s research platform. Ganite® (gallium nitrate injection) is the company’s leading drug in the Small Molecule program. Ganite is exclusively marketed in the U.S. to treat symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. For further information, visit the Company’s web site at www.genta.com.
- 17 years ago
QualityStocks
Generex Biotechnology Corporation (NASDAQ: GNBT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – AI-Driven Energy Demands Highlight Strategic Value of Platinum Group Metals Ltd.’s (NYSE American: PLG) (TSX: PTM) Waterberg Project
As the rise of AI-generated services places extreme pressure on the global power grid, Platinum Group…
-
QualityStocksNewsBreaks – Spotlight on ONAR Holding Corp.’s (ONAR) Strategic Playbook: AI-Optimized Campaigns
ONAR (OTCQB: ONAR) was featured in a recent article that discussed its strategy amid the AI…
-
QualityStocksNewsBreaks – Why AI Maverick Intel Inc. (BINP) Is ‘One to Watch’
AI Maverick Intel (OTCID: BINP) recently rebranded and adopted a new strategic direction focused on…